A compensation at these levels will hurt the longs once again. Any potential news could double or triple the pps for insiders while many "longs" are trying to breakeven. Why not produce a Nasdaq listing first and than compensate at realistic levels !!! The only way to survive is institutional support and unless clarified we must assume $4 pps to meet the requirement or is it still 5 days @2??? Chinese New year around the corner and nothing will get done .....it may turn into another China "Houdini" deal. If company expectations are so high but no "domestic" Big Pharma interest it raises a RED flag !! All acquisitions were supposed to be turn key revenue and could have reduced toxic funding/dilution. Compensate after positive results and stop bs dilution, insiders imo will dump before meeting listing requirement and possibly create additional delays ..................it doesn't appear Nasdaq is a priority!!
(3)
(3)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links